JP7500555B2 - ヒト免疫不全ウイルス複製の阻害剤 - Google Patents

ヒト免疫不全ウイルス複製の阻害剤 Download PDF

Info

Publication number
JP7500555B2
JP7500555B2 JP2021521995A JP2021521995A JP7500555B2 JP 7500555 B2 JP7500555 B2 JP 7500555B2 JP 2021521995 A JP2021521995 A JP 2021521995A JP 2021521995 A JP2021521995 A JP 2021521995A JP 7500555 B2 JP7500555 B2 JP 7500555B2
Authority
JP
Japan
Prior art keywords
chloro
indazol
ethyl
mmol
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021521995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505597A5 (cg-RX-API-DMAC7.html
JP2022505597A (ja
Inventor
ピー ギリス,エリック
ナイドゥ,ビー.ナラシムフル
イー. パーセラ,カイル
パテル,マノイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare UK No 5 Ltd
Original Assignee
ViiV Healthcare UK No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ViiV Healthcare UK No 5 Ltd filed Critical ViiV Healthcare UK No 5 Ltd
Publication of JP2022505597A publication Critical patent/JP2022505597A/ja
Publication of JP2022505597A5 publication Critical patent/JP2022505597A5/ja
Application granted granted Critical
Publication of JP7500555B2 publication Critical patent/JP7500555B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021521995A 2018-10-25 2019-10-22 ヒト免疫不全ウイルス複製の阻害剤 Active JP7500555B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862750395P 2018-10-25 2018-10-25
US62/750,395 2018-10-25
PCT/IB2019/059004 WO2020084480A1 (en) 2018-10-25 2019-10-22 Inhibitors of human immunodeficiency virus replication

Publications (3)

Publication Number Publication Date
JP2022505597A JP2022505597A (ja) 2022-01-14
JP2022505597A5 JP2022505597A5 (cg-RX-API-DMAC7.html) 2022-10-11
JP7500555B2 true JP7500555B2 (ja) 2024-06-17

Family

ID=68344929

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521995A Active JP7500555B2 (ja) 2018-10-25 2019-10-22 ヒト免疫不全ウイルス複製の阻害剤

Country Status (6)

Country Link
US (1) US20210393633A1 (cg-RX-API-DMAC7.html)
EP (1) EP3870575B1 (cg-RX-API-DMAC7.html)
JP (1) JP7500555B2 (cg-RX-API-DMAC7.html)
ES (1) ES2942998T3 (cg-RX-API-DMAC7.html)
PT (1) PT3870575T (cg-RX-API-DMAC7.html)
WO (1) WO2020084480A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019198024A1 (en) * 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
MA53973A (fr) 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd Inhibiteurs de la réplication du virus de l'immunodéficience humaine
WO2020084491A1 (en) * 2018-10-24 2020-04-30 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
ES2969030T3 (es) * 2018-10-29 2024-05-16 Viiv Healthcare Uk No 5 Ltd Derivados de quinazolinil-indazol y su uso como inhibidores de replicación de virus de inmunodeficiencia humana
US20220211704A1 (en) * 2019-04-30 2022-07-07 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
IL291436B1 (en) * 2019-09-20 2026-07-01 Ideaya Biosciences Inc History of indole and indazole sulfonamido 4-mutates as PARG inhibitors
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
WO2021070054A1 (en) * 2019-10-08 2021-04-15 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US12564595B2 (en) 2019-11-28 2026-03-03 Shionogi & Co., Ltd. Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於hiv之治療性化合物
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
WO2025169059A1 (en) 2024-02-05 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504392A (ja) 2013-01-09 2016-02-12 ギリアード サイエンシーズ, インコーポレイテッド 抗レトロウイルス剤としての(ヘテロ)アリールアセトアミド誘導体
JP2016510038A (ja) 2013-03-01 2016-04-04 ギリアード サイエンシーズ, インコーポレイテッド Hivの処置のためのアミド化合物
JP2017525722A (ja) 2014-08-29 2017-09-07 ギリアード サイエンシーズ, インコーポレイテッド 抗レトロウイルス剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
EP2943493B1 (en) 2013-01-09 2017-08-02 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
LT3347352T (lt) 2016-08-19 2019-08-12 Gilead Sciences, Inc. Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
TW201906834A (zh) * 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
KR102847339B1 (ko) 2018-02-16 2025-08-19 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
WO2019198024A1 (en) * 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
JP2022506399A (ja) * 2018-11-05 2022-01-17 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504392A (ja) 2013-01-09 2016-02-12 ギリアード サイエンシーズ, インコーポレイテッド 抗レトロウイルス剤としての(ヘテロ)アリールアセトアミド誘導体
JP2016510038A (ja) 2013-03-01 2016-04-04 ギリアード サイエンシーズ, インコーポレイテッド Hivの処置のためのアミド化合物
JP2017525722A (ja) 2014-08-29 2017-09-07 ギリアード サイエンシーズ, インコーポレイテッド 抗レトロウイルス剤

Also Published As

Publication number Publication date
US20210393633A1 (en) 2021-12-23
WO2020084480A1 (en) 2020-04-30
PT3870575T (pt) 2023-05-12
EP3870575A1 (en) 2021-09-01
ES2942998T3 (es) 2023-06-08
JP2022505597A (ja) 2022-01-14
EP3870575B1 (en) 2023-03-29

Similar Documents

Publication Publication Date Title
JP2022505597A (ja) ヒト免疫不全ウイルス複製の阻害剤
JP7526174B2 (ja) キナゾリニル-インダゾール誘導体及びそのヒト免疫不全ウイルス複製の阻害剤としてのその使用
JP7433303B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
JP7532354B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
JP7398448B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
JP7361766B2 (ja) ヒト免疫不全ウイルス複製の阻害剤
US20240374598A1 (en) Inhibitors of human immunodeficiency virus replication
JP2022509919A (ja) ヒト免疫不全ウイルス複製の阻害剤
TW201906834A (zh) 人類免疫不全病毒複製之抑制劑
JP2021521131A (ja) ヒト免疫不全ウイルス複製の阻害剤としての4−オキソ−3,4−ジヒドロキナゾリン化合物
AU2025204180A9 (en) MASP-2 inhibitors and methods of use
JP7545414B2 (ja) ヒト免疫不全ウイルス複製阻害剤
CN115397424A (zh) 人类免疫缺陷病毒复制的抑制剂
TW202128648A (zh) 人類免疫不全病毒複製之抑制劑
CN116323585A (zh) 新化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220928

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231010

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240409

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240605

R150 Certificate of patent or registration of utility model

Ref document number: 7500555

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150